Clinical Trial

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-29
Trial Details
NCT Number NCT07512362
Lead Sponsor Bernard (Barry) Baumel
Conditions Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Enrollment 10 participants
Start Date 2026-05-15
Primary Completion 2028-06-15 (estimated)
Study Completion 2028-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-28